OHSU researcher announces dramatic breakthrough in leukemia treatment

November 29, 1999

Experimental Compound Targets Molecular Cause of Disease

Portland, Ore. - Patients with chronic myelogenous leukemia are finding new hope in an experimental pill developed by Oregon Health Sciences University researcher Brian Druker, M.D., in collaboration with scientists at Novartis Pharmaceuticals. Early clinical trials are producing dramatic results with minimal side effects.

Unlike chemotherapy, which kills both normal and abnormal cells in an attempt to eradicate the cancer, the compound STI-571 targets an enzyme found only in the leukemia cells. The result is a halt to the progression of the disease.

Druker will present Phase I clinical trial results at the American Society of Hematology conference in New Orleans on Dec. 5. The trial, conducted at OHSU in conjunction with Moshe Talpaz, M.D., at the M.D. Anderson Cancer Center in Houston and Charles Sawyers, M.D., the Jonsson Cancer Center at UCLA, involved CML patients who had failed to respond to standard treatment for their leukemia. Once an STI-571 dosage of 300 mg or greater was established, 31 of 31 patients in the study had a complete normalization of their blood counts, signaling a remission of the disease. Even more remarkable, in some cases the molecular cause of the disease seemed to disappear.

"I congratulate these investigators on pushing forward the field of rationally targeted cancer therapy," said Richard Klausner, M.D., director of the National Cancer Institute. "While too soon to evaluate the ultimate value of this agent for the standard clinical approach to CML, their early data are very encouraging."

"The early evidence of effectiveness of agent STI-571 heralds a new approach to leukemia therapy and perhaps that of other cancers as well, that is, the specific inactivation of the cancer-causing protein in malignant cells," said Marshall Lichtman, M.D., executive vice president for research and medical affairs of the Leukemia Society of America. "These preliminary results should engender excitement for researchers and physicians battling leukemia and new hope for affected patients. The Leukemia Society of America, on behalf of its donors and the patients we serve, is very pleased to have played an integral role in supporting this landmark research."

CML affects approximately 6,000 Americans a year and is characterized by an excessive proliferation of white blood cells. The disease is caused by a chromosomal defect that produces an abnormal enzyme called BCR-ABL, which is responsible for the overabundance of white blood cells. STI-571 was engineered to inhibit the activity of BCR-ABL.

"The potential significance of this type of research extends beyond leukemia," said Druker, whose research is supported in part by the Leukemia Society and the National Cancer Institute. "One of the major goals of cancer research has been to identify differences between cancer cells and normal cells so that these differences can be targeted with more effective and less toxic treatments. That1s exactly what we've seen happen in these patients."

A Phase II trial, which will introduce the compound to a broader group of patients, is scheduled to begin in early 2000.

Oregon Health & Science University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.